🔎 Trials Near Me

Beranda › Karsinoma Neuroendokrin › Maryland

Uji klinis Karsinoma Neuroendokrin di Maryland

6 studi untuk Karsinoma Neuroendokrin mencari peserta di lokasi di Maryland.

Teks studi resmi (Bahasa Inggris)

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

  • National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06406465

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  • National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07509034

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

  • National Institutes of Health Clinical Center, Bethesda
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05237934

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

  • United Theranostics, Glen Burnie
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07278479

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05652686

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

  • National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06041516

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.